This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A compound of formula I



I

in which

R is -OH, -OA, phenoxy, Ar, -O-CO-A, SO_3H, SO_3A, $-OSO_3H$, $-OSO_3A$, $-OSO_2A$, SO_2A, Hal, COOH, COOA, $CONH_2$, $NHSO_2A$, COA, CHO or SO_2NH_2, or

two radicals R together are methylenedioxy or ethylenedioxy,

X is OH, or

two radicals X together are methylenedioxy or ethylenedioxy,

Ar is phenyl which is unsubstituted or monosubstituted, disubstituted or trisubstituted by A,

A is an unbranched or branched alkyl having 1-10 carbon atoms, in which 1-7 H atoms are optionally replaced by F,

Hal is F, Cl, Br or I,

n is 1, 2, 3 or 4, and

m is 1, 2, 3, 4 or 5, or

a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof.

2. (Original) A compound according to Claim 1,

in which

R is -OH or -OA, and

X is OH, or

a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof.

3. (Original) A compound according to Claim 1,

in which

R is -OH or -OA,

X is OH,

A is an unbranched or branched alkyl having 1-6 carbon atoms,

n is 1 or 2, and

m is 1, 2 or 3, or

a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof.

4. (Original) A compound according to Claim 1,

in which

R is -OH or -OA, or

two radicals R together are methylenedioxy or ethylenedioxy,

X is OH,

A is an unbranched or branched alkyl having 1-6 carbon atoms,

n is 1 or 2, and

m is 1, 2 or 3, or

a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof.

5. (Original) A compound according to Claim 1 selected from

5-hydroxy-2-(2',4'-dihydroxybenzoyl)chromone,

5-hydroxy-2-(2'-hydroxy-4',5'-methylenedioxybenzoyl)chromone,

6-hydroxy-2-(2'-hydroxy-4',5'-methylenedioxybenzoyl)chromone, or

6,7-methylenedioxy-2-(2'-hydroxy-4',5'-methylenedioxybenzoyl)chromone, or

a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof.

6. (Original) A process for preparing a compound according to Claim 1 or a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof comprising

a) reacting a compound of formula II



II

in which
X and n are as defined in Claim 1,
with a compound of formula III



III

in which A is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,
to give a compound of formula IV



IV

in which X and n are as defined in Claim 1, and A is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

b) then hydrolysing the compound of formula IV to a compound of formula V



V

in which X and n are as defined in Claim 1,

c) then converting the compound of formula V to a compound of formula VI



VI

in which X and n are as defined in Claim 1,
and then reacting the compound of formula VI with a compound of formula VII



VII

in which R and m are as defined in Claim 1,
in a Friedel-Crafts acylation to give a compound of the formula I,

and/or

d) a compound of formula I is converted into a salt or into a solvate and/or a stereoisomer of a compound of formula I is isolated.

7. (Original) A pharmaceutical composition comprising a compound according to Claim 1 or a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof and one or more pharmaceutically acceptable excipients and/or adjuvants.

8. (Original) A method of inhibiting tyrosine kinase comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.

9. (Original) A method of treating a solid tumor in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.

10. (Original) A method according to Claim 9, wherein the solid tumor is a cerebral tumor, a tumor of the genito-urinary tract, a tumor of the lymphatic system, a stomach tumor, a laryngeal tumor or a lung tumor.

11. (Original) A method according to Claim 9, wherein the solid tumor is monocytic leukaemia, lung adenocarcinoma, small cell lung carcinoma, pancreatic cancer, glioblastoma or breast carcinoma.

12. (Original) A method of treating a disease by inhibiting angiogenesis in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.

13. (Original) A method according to Claim 12, wherein the disease is an ocular disease.

14. (Original) A method of treating retinal vascularisation in a mammal

comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.

15. (Original) A method of treating diabetic retinopathy in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.

16. (Original) A method of treating an age-related macular degeneration in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.

17. (Original) A method of treating an inflammatory disease in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.

18. (Original) A method according to claim 17, wherein the inflammatory disease is rheumatoid arthritis, psoriasis, contact dermatitis or a delayed hypersensitivity reaction.

19. (Original) A method of treating a tyrosine kinase-dependent disease or a tyrosine kinase-dependent condition in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.

20. (Original) A method of treating a bone pathology comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.

21. (Original) A method according to claim 20, wherein the bone pathology is osteosarcoma, osteoarthritis or rickets.

22. (Original) A pharmaceutical composition according to claim 7, further

comprising an additional pharmaceutically active compound.

23. (Original) A kit comprising separate packs of

(a) a pharmaceutical composition according to Claim 7 or a compound of formula I or a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof,

and

(b) an additional pharmaceutically active compound or composition.

24. (Original) A method according to claim 9, further comprising administering an oestrogen receptor modulator, an androgen receptor modulator, a retinoid receptor modulator, a cytotoxic agent, an antiproliferative agent, a prenyl-protein transferase inhibitor, an HMG-CoA reductase inhibitor, an HIV protease inhibitor, a reverse transcriptase inhibitor or an angiogenesis inhibitor.

25. (Original) A method according to claim 24, further comprising performing radiotherapy on said mammal.

26. (Original) A method of treating a disease related to an oxidative stress condition in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.

27. (Original) A method according to claim 25, wherein the disease is memory loss or a neurodegenerative disorder.

28. (Original) A food supplement comprising a compound of claim 1.

29. (Original) A cosmetic composition comprising a compound of claim 1.

30. (Original) A method of protecting the proteins of the skin from stress

comprising applying a cosmetic composition of claim 29 to the skin.

31. (Original) A topically applicable cosmetic composition comprising a compound of claim 1.

32. (Currently Amended) A cosmetic composition ~~according to claim 29~~, containing 0.0001 to 50% by weight of a compound of claim 1.

33. (Original) A compound of formula VI



VI

in which

X is OH, or

two radicals X together are methylenedioxy or ethylenedioxy, and

n is 1, 2, 3 or 4, or a

salt thereof.